Buy UR-144 Powder Online


SKU: Buy UR-144 Powder Online Category:
VariationPriceStatusQuantityAdd To Cart
10 grs $70.00instock
Add to cart
100 grs $395.00instock
Add to cart
250 grs $690.00instock
Add to cart
50 grs $230.00instock
Add to cart
500 grs $1,350.00instock
Add to cart
999 grs $2,280.00instock
Add to cart


Buy UR-144 Powder

Buy UR-144 Powder (TMCP-018, KM-X1, MN-001, YX-17) is a drug invented by Abbott Laboratories, that acts as a selective full agonist of the peripheral cannabinoid receptor CB2, but with much lower affinity for the psychoactive CB1 receptor.


UR-144 has high affinity for the CB2 receptor with a Ki of 1.8 nM but 83x lower affinity for the CB1 receptor with a Ki of 150 nM. It was found to possess an EC50 of 421 nM for human CB1 receptors, and 72 nM for human CB2 receptors. UR-144 produces bradycardia and hypothermia in rats at a dose of 10 mg/kg, suggesting weak cannabinoid-like activity.

Chemically it is closely related to other 2,2,3,3-tetramethylcyclopropyl synthetic cannabinoids like A-796,260 and A-834,735 but with a different substitution on the 1-position of the indole core, in these compounds its 1-pentyl group is replaced with alkylheterocycles like 1-(2-morpholinoethyl) and 1-(tetrahydropyran-4-ylmethyl).

Chemical and physical data

Formula: C21H29NO

Molar mass: 311.461 g/mol g·mol−1


Inhalation (tentative due to a lack of information)

  • Range: 2.5 to 20 mg

Most people have been exposed to the drug in the form of “blends” that contain varying levels of UR-144. It’s not wise to use those products.


Inhalation (tentative due to a lack of information)

  • Total: 1 – 2 hours
  • Onset: Under 10 minutes

See also

  • AB-001
  • AM-1221
  • FAB-144
  • JTE 7-31
  • JWH-018
  • N-(S)-Fenchyl-1-(2-morpholinoethyl)-7-methoxyindole-3-carboxamide
  • XLR-11
  • Tetramethylcyclopropylfentanyl

Additional information


10 grs, 100 grs, 250 grs, 50 grs, 500 grs, 999 grs


There are no reviews yet.

Be the first to review “Buy UR-144 Powder Online”

Your email address will not be published. Required fields are marked *